The actions of a novel potent islet β-cell-specific ATP-sensitive K+ channel opener can be modulated by syntaxin-1A acting on sulfonylurea receptor 1

Diabetes

Volumn 56, Issue 8, 2007, Pages 2124-2134

  Ng, Betty ^a   Kang, Youhou ^a   Elias, Chadwick L ^a   He, Yan ^a   Xie, Huanli ^a   Hansen, John B ^b   Wahl, Philip ^b   Gaisano, Herbert Y ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 3 (1 METHYLCYCLOBUTYL)AMINO 4H THIENO[3,2 E] 1,2,4 THIADIAZINE 1,1 DIOXIDE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; DIAZOXIDE; GLUTATHIONE TRANSFERASE; GREEN FLUORESCENT PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; NNC 55 0462; SULFONYLUREA RECEPTOR 1; SYNTAXIN 1A; SYNTAXIN 2; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL MEMBRANE; CELLS, CULTURED; DIAZOXIDE; ELECTROPHYSIOLOGY; HUMANS; ISLETS OF LANGERHANS; MALE; MOLECULAR STRUCTURE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; SYNTAXIN 1;

EID: 34547600534     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db07-0030     Document Type: Article

References (50)

1. Leahy JL: Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36:197-209, 2005
2. Rhodes CJ: Type 2 diabetes - a matter of beta-cell life and death? Science 307:380-384, 2005
3. Gerber SH, Sudhof TC: Molecular determinants of regulated exocytosis. Diabetes 51 (Suppl. 1):S3-S11, 2002
4. Daniel S, Noda M, Straub SG, Sharp GW: Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion. Diabetes 48:1686-1690, 1999
5. Chan CB, MacPhail RM, Sheu L, Wheeler MB, Gaisano HY: Beta-cell hypertrophy in fa/fa rats is associated with basal glucose hypersensitivity and reduced SNARE protein expression. Diabetes 48:997-1005, 1999
6. Gaisano HY, Ostenson CG, Sheu L, Wheeler MB, Efendic S: Abnormal expression of pancreatic islet exocytotic soluble N-ethylmaleimide-sensitive factor attachment protein receptors in Goto-Kakizaki rats is partially restored by phlorizin treatment and accentuated by high glucose treatment. Endocrinology 143:4218-4226, 2002
7. Nagamatsu S, Nakamichi Y, Yamamura C, Matsushima S, Watanabe T, Ozawa S, Furukawa H, Ishida H: Decreased expression of t-SNARE, syntaxin 1, and SNAP-25 in pancreatic beta-cells is involved in impaired insulin secretion from diabetic GK rat islets: restoration of decreased t-SNARE proteins improves impaired insulin secretion. Diabetes 48:2367-2373, 1999
8. Ostenson CG, Gaisano H, Sheu L, Tibell A, Bartfai T: Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients. Diabetes 55:435-440, 2006
9. Grill V, Bjorklund A: Overstimulation and beta-cell function. Diabetes 50 (Suppl. 1):S122-S124, 2001
10. i abnormalities in human pancreatic islets: important role of overstimulation. Diabetes 49:1840-1848, 2000
11. Hosokawa YA, Leahy JL: Parallel reduction of pancreas insulin content and insulin secretion in 48-h tolbutamide-infused normoglycemic rats. Diabetes 46:808-813, 1997
12. Porte D Jr: Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 17:181-188, 2001
13. Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P: Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem 11:1595-1615, 2004
14. Ashcroft FM, Gribble FM: ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 42:903-919, 1999
15. Seino S: ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 61:337-362, 1999
16. Song SH, Rhodes CJ, Veldhuis JD, Butler PC: Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology 144:3399-3405, 2003
17. Yoshikawa H, Ma Z, Bjorklund A, Grill V: Short-term intermittent exposure to diazoxide improves functional performance of beta-cells in a high-glucose environment. Am J Physiol Endocrinol Metab 287:E1202-E1208, 2004
18. Matsuda M, Kawasaki F, Mikami Y, Takeuchi Y, Saito M, Eto M, Kaku K: Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes. Eur J Pharmacol 453:141-148, 2002
19. Hiramatsu S, Hoog A, Moller C, Grill V: Treatment with diazoxide causes prolonged improvement of beta-cell function in rat islets transplanted to a diabetic environment. Metabolism 49:657-661, 2000
20. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427-1430, 1996
21. Ortqvist E, Bjork E, Wallensteen M, Ludvigsson J, Aman J, Johansson C, Forsander G, Lindgren F, Berglund L, Bengtsson M, Berne C, Persson B, Karlsson FA: Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 27:2191-2197, 2004
22. Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U: Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 28:448-456, 2002
23. Hansen JB: Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 13:361-376, 2006
24. Dabrowski M, Ashcroft FM, Ashfield R, Lebrun P, Pirotte B, Egebjerg J, Bondo Hansen J, Wahl P: The novel diazoxide analog 3-isopropylamino-7-methoxy- 4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes 51:1896-1906, 2002
25. Dabrowski M, Larsen T, Ashcroft FM, Bondo Hansen J, Wahl P: Potent and selective activation of the pancreatic beta-cell type K(ATP) channel by two novel diazoxide analogues. Diabetologia 46:1375-1382, 2003
26. de Tullio P, Becker B, Boverie S, Dabrowski M, Wahl P, Antoine MH, Somers F, Sebille S, Ouedraogo R, Hansen JB, Lebrun P, Pirotte B: Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides. J Med Chem 46:3342-3353, 2003
27. Nielsen FE, Bodvarsdottir TB, Worsaae A, MacKay P, Stidsen CE, Boonen HC, Pridal L, Arkhammar PO, Wahl P, Ynddal L, Junager F, Dragsted N, Tagmose TM, Mogensen JP, Koch A, Treppendahl SP, Hansen JB: 6-chloro-3-alkylamino-4H- thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells. J Med Chem 45:4171-4187, 2002
28. Carr RD, Brand CL, Bodvarsdottir TB, Hansen JB, Sturis J: NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes 52:2513-2518, 2003
29. Rasmussen SB, Sorensen TS, Hansen JB, Mandrup-Poulsen T, Hornum L, Markholst H: Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats. Horm Metab Res 32:294-300, 2000
30. Maedler K, Storling J, Sturis J, Zuellig RA, Spinas GA, Arkhammar PO, Mandrup-Poulsen T, Donath MY: Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 53:1706-1713, 2004
31. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC: Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 89:795-805, 2004
32. Skak K, Gotfredsen CF, Lundsgaard D, Hansen JB, Sturis J, Markholst H: Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 53:1089-1095, 2004
33. Cui N, Kang Y, He Y, Leung YM, Xie H, Pasyk EA, Gao X, Sheu L, Hansen JB, Wahl P, Tsushima RG, Gaisano HY: H3 domain of syntaxin 1A inhibits KATP channels by its actions on the sulfonylurea receptor 1 nucleotide-binding folds-1 and -2. J Biol Chem 279:53259-53265, 2004
34. Pasyk EA, Kang Y, Huang X, Cui N, Sheu L, Gaisano HY: Syntaxin-1A binds the nucleotide-binding folds of sulphonylurea receptor 1 to regulate the KATP channel. J Biol Chem 279:4234-4240, 2004
35. Kang Y, Leung YM, Manning-Fox JE, Xia F, Xie H, Sheu L, Tsushima RG, Light PE, Gaisano HY: Syntaxin-1A inhibits cardiac KATP channels by its actions on nucleotide binding folds 1 and 2 of sulfonylurea receptor 2A. J Biol Chem 279:47125-47131, 2004
36. Bray KM, Quast U: A specific binding site for K+ channel openers in rat aorta. J Biol Chem 267:11689-11692, 1992
37. Quast U, Stephan D, Bieger S, Russ U: The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 53 (Suppl. 3):S156-S164, 2004
38. Wheeler MB, Sheu L, Ghai M, Bouquillon A, Grondin G, Weller U, Beaudoin AR, Bennett MK, Trimble WS, Gaisano HY: Characterization of SNARE protein expression in beta cell lines and pancreatic islets. Endocrinology 137:1340-1348, 1996
39. Bennett MK, Garcia-Arraras JE, Elferink LA, Peterson K, Fleming AM, Hazuka CD, Scheller RH: The syntaxin family of vesicular transport receptors. Cell 74:863-873, 1993
40. Nagamatsu S, Fujiwara T, Nakamichi Y, Watanabe T, Katahira H, Sawa H, Akagawa K: Expression and functional role of syntaxin 1/HPC-1 in pancreatic beta cells. Syntaxin 1A, but not 1B, plays a negative role in regulatory insulin release pathway. J Biol Chem 271:1160-1165, 1996
41. Trus M, Wiser O, Goodnough MC, Atlas D: The transmembrane domain of syntaxin 1A negatively regulates voltage-sensitive ca(2+) channels. Neuroscience 104:599-607, 2001
42. Lu Q, AtKisson MS, Jarvis SE, Feng ZP, Zamponi GW, Dunlap K: Syntaxin 1A supports voltage-dependent inhibition of alpha1B Ca2+ channels by gbetagamma in chick sensory neurons. J Neurosci 21:2949-2957, 2001
43. Leung YM, Kang Y, Gao X, Xia F, Xie H, Sheu L, Tsuk S, Lotan I, Tsushima RG, Gaisano HY: Syntaxin 1A binds to the cytoplasmic C terminus of Kv2.1 to regulate channel gating and trafficking. J Biol Chem 278:17532-17538, 2003
44. Babenko AP, Gonzalez G, Bryan J: Pharmaco-topology of sulfonylurea receptors. separate domains of the regulatory subunits of K(ATP) channel isoforms are required for selective interaction with K(+) channel openers. J Biol Chem 275:717-720, 2000
45. Gribble FM, Reimann F: Pharmacological modulation of K(ATP) channels. Biochem Soc Trans 30:333-339, 2002
46. Hambrock A, Loffler-Walz C, Kurachi Y, Quast U: Mg2+ and ATP dependence of K(ATP) channel modulator binding to the recombinant sulphonylurea receptor, SUR2B. Br J Pharmacol 125:577-583, 1998
47. Schwanstecher M, Sieverding C, Dorschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, Bryan J: Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 17:5529-5535, 1998
48. Bienengraeber M, Alekseev AE, Abraham MR, Carrasco AJ, Moreau C, Vivaudou M, Dzeja PP, Terzic A: ATPase activity of the sulfonylurea receptor: a catalytic function for the KATP channel complex. FASEB J 14:1943-1952, 2000
49. Lam PP, Leung YM, Sheu L, Ellis J, Tsushima RG, Osborne LR, Gaisano HY: Transgenic mouse overexpressing syntaxin-1A as a diabetes model. Diabetes 54:2744-2754, 2005
50. Alemzadeh R, Fledelius C, Bodvarsdottir T, Sturis J: Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. Metabolism 53:441-447, 2004